Stage I Renal Cell Cancer
12
3
4
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
3 terminated out of 12 trials
57.1%
-29.4% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
Prehabilitation Prior to Surgery for Kidney Tumors
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies